



CASE TX/4-100-8388C
(167-51)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
MEINZER ET AL.

ART UNIT: 1615

APPLICATION NO: 10/781,069

EXAMINER: Channavajjala, L.S.

FILED: FEBRUARY 18, 2004

FOR: OIL-FREE PHARMACEUTICAL COMPOSITIONS CONTAINING
CYCLOSPORIN A

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Novartis AG, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056, represents that it is the assignee and owner of the entire interest in the above-identified application by virtue of an assignment, which was recorded in the United States Patent and Trademark Office on October 23, 2001 at Reel/Frame 012525/0981

Novartis AG hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173 as presently shortened by any terminal disclaimer of the first to expire of U.S. Patents 6,432,445 and 6,767,555, issued August 13, 2002 and July 27, 2004, respectively. U.S. Patents 6,432,445 and 6,767,555 are also assigned to Novartis AG by virtue of an assignment which was recorded in the United States Patent and Trademark Office on June 24, 2002, at Reel/Frame 013031/0062.

Novartis AG hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and said patents are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Novartis AG does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of the first to expire of U.S. Patents 6,432,445 and 6,767,555, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate; is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 16th day of April, 2009, by the undersigned attorney of record.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-9308



Leslie Fischer
Attorney for Applicants
Reg. No. 58,393